Biogen Inc. guided investors to expect a gradual launch of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA) during its fourth quarter sales and earnings call Jan. 26. The cautious outlook is notable because Spinraza is the first life-transforming medicine approved for the devastating rare neurodegenerative disease – not a drug entering a competitive therapeutic category.
Biogen Forecasts Gradual Launch For Life-Transforming Drug Spinraza
The biotech said it has had some early “challenges” securing reimbursement for Spinraza, which it priced at $750,000 for the first year of treatment for the rare disease spinal muscular atrophy
More from Business
More from Scrip
• By
The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.
• By
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
• By
AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.